These trials underscore the therapeutic value of CD20 inhibitor–venetoclax and BCRi–venetoclax combinations, establishing venetoclax as a critical option, especially for relapsed or refractory CLL. The gene discussed is MS4A1; the disease is B-cell chronic lymphocytic leukemia.